Managing your WIRB approved study Presented by: Carmen Thompson, - - PDF document

▶
managing your wirb approved study
SMART_READER_LITE
LIVE PREVIEW

Managing your WIRB approved study Presented by: Carmen Thompson, - - PDF document

Aug 15, 2023 142 likes •327 views

5/8/2020 Managing your WIRB approved study Presented by: Carmen Thompson, CIP Agenda Managing your site in Connexus Changes in Research (Modifications) Other Submissions Continuing Reviews Promptly Reportable Information

slide-1
SLIDE 1

5/8/2020 1

Managing your WIRB approved study

Presented by: Carmen Thompson, CIP

 Managing your site in Connexus  Changes in Research (Modifications)  Other Submissions

  • Continuing Reviews
  • Promptly Reportable Information (PRI)
  • Closures

Agenda

2

slide-2
SLIDE 2

5/8/2020 2

Managing Your Site in Connexus

Managing Your Site in Connexus

4

If you are listed as a site contact on the initial review submission form, you will be added to the workspace automatically if you have a corresponding Connexus account

Email address on form must match the registered Connexus email address

slide-3
SLIDE 3

5/8/2020 3

Connexus

5

https://portal.wcgclinical.com http://www.wirb.com

Managing Your Site in Connexus

6

Locate in Connexus under My Investigators

slide-4
SLIDE 4

5/8/2020 4

Managing Your Site in Connexus

7

Locate in Connexus under My Investigators

Managing Your Site in Connexus

8

Locate in Connexus under My Investigators

Approval documents displayed here Click to view or make submissions Click to manage access to this site workspace only

slide-5
SLIDE 5

5/8/2020 5

Managing Your Site in Connexus

9

View submissions for this Investigator

  • Allows you to see all submissions made for the site
  • Auto restricted to the last 30 days
  • Submitted since field: change to Anytime, Last Week-Month-Year

Managing Your Site in Connexus

10

Make a submission for this Investigator - all Submissions Options

  • Protocol Changes (Revised Protocol, Amendments, etc.)
  • Change in Research Location
  • Modified or Additional Recruitment Materials
  • New or Changed Subject Materials
  • New Consent Forms
  • Consent Form Modifications
  • Continuing Review Reports Form
  • Contact Information Update Forms
  • Closure Reports
  • Promptly Reportable Information Forms
  • Planned Protocol Deviations
slide-6
SLIDE 6

5/8/2020 6

Changes in Research (Modifications)

Smart PDF forms are available in two locations:

WIRB.com > Download Forms Page

Via Connexus Quick Access Links > IRB Forms and Guides

Change in Research Submissions

12

slide-7
SLIDE 7

5/8/2020 7

Change in Research Submissions

13

CHLA allows sponsors to submit on your behalf

Be sure to confirm with the sponsor/CRO if they will be submitting to WIRB for you

If they will not, you will need to make all amendments, revisions, and modifications change in research submissions to WIRB Consent Form Modifications

 CHLA initiated changes must have CHLA clearance before

submitting to WIRB

 Changes initiated by the sponsor do not require CHLA clearance  When CHLA makes changes to consent forms, they must include:

  • Updated language using tracked (redline) changes
  • Use the latest CHLA-specific WIRB approved version

Change in Research Submissions

14

slide-8
SLIDE 8

5/8/2020 8

Change in Principal Investigator (PI)

 This would be a CHLA initiated change, must have CHLA

clearance before submitting to WIRB

 WIRB submission will require:

  • An initial review submission form for the new PI – be sure to complete PI transfer section
  • Submit PI medical license and CV, if not on file at WIRB
  • Financial disclosure form and COI Management plan, if applicable
  • CHLA Clearance letter

Change in Research Submissions

15

Change in Principal Investigator (PI)

 Will there be consent/assent form updates with the change in PI?

  • If PI contact information is the only update required - WIRB use the information from the

submission and update the consent and assent form (if using sponsor assent template)

  • NOTE: If using the CHLA assent form template, please submit an updated CHLA assent

form and submit as subject material

  • Additional changes to the consent/assent form(s), must follow the process outlined on the

previous slide (i.e. updated language must be tracked (redlined) on the latest WIRB approved version)

Change in Research Submissions

16

slide-9
SLIDE 9

5/8/2020 9

If you have to submit, amendments and modifications can be submitted using our “Change in Research” form

 Check all the required changes and

submit all supporting documents for the change

Change in Research Submissions

17

Planned Protocol Deviations Must Have IRB Approval

 Allow 2-3 business days to process  All parties must be in agreement:

  • Correspondence from PI and sponsor/CRO/monitor

 Use the change in research form to provide

  • Date, Description, How it deviates from the protocol, Reason for

deviating from the protocol  Submit via Connexus, type “Planned protocol variance”

Change in Research Submissions

18

slide-10
SLIDE 10

5/8/2020 10

Ensure that you comply with your local CHLA requirements for amendments:

When amendments are approved by WIRB, submit an amendment in iStar and upload the certificate of action (approval letter), approved consent/assent form(s)

The revised protocol and other WIRB approved documents do not need to be uploaded in iStar. Keep these documents in your regulatory binder per CHLA policy.

Change in Research Submissions

19

Other Submissions

slide-11
SLIDE 11

5/8/2020 11

Continuing Review Report Form (CRRF) will be sent automatically to all individual(s) listed on the Initial Review form

Continuing Review

21

NOTE: The above fields will be filled in for you. This form is emailed to the all study contacts listed on the Initial Review Submission form.

 If you receive initial approval within 90 days of the protocol expiration date, you will automatically be brought on to the next continuing review period – no need to provide a CRRF  Forms are sent out approximately 80 days before the study expiration date, and are due approximately 56 days before the study expiration date

  • All study contacts will receive the CRRF via email

 All sites expiration dates are aligned with protocol expiration date

  • Be sure to check you protocol expiration on your certificate of action

 CRRF are reviewed up to 30 days before expiration date

Continuing Review

22

slide-12
SLIDE 12

5/8/2020 12 Reminder:

Failure to complete and return the attached report will be considered non- compliance. If you do not complete and return the continuing review report, the Board may take action to suspend or terminate approval of this research at your location. If approval is suspended or terminated, this will be reported to the FDA or other appropriate regulatory agencies.

Continuing Review

23

Ensure that you comply with your local CHLA requirements for continuing reviews:

When continuing review is approved by WIRB, submit an amendment in iStar and upload the certificate of action (approval letter).

NOTE: WIRB does not issue new approval of consent/assent form(s) at continuing review.

New approval of consent/assent form(s) are only Issued when an action is taken on the consent/assent form(s).

Continuing Review

24

slide-13
SLIDE 13

5/8/2020 13

IMPORTANT: Update the contacts who receive IRB correspondence

Contact Information Update Form

25

Promptly Reportable Information (PRI) form is used to report all items that require reporting to WIRB within 5 business days of discovery Refer to WCG Guide for Researchers to determine the kind

  • f information that requires Prompt
  • Reporting. This may differ from

CHLA’s reporting requirement.

WIRB Reportable Information Form

26

slide-14
SLIDE 14

5/8/2020 14

 Audit, inspection, or inquiry by a federal agency  Written report from a federal agency (e.g., FDA Form 483)  State medical board action or hospital medical staff action  Allegation of Noncompliance or Finding of Noncompliance  Suspension or premature termination by the sponsor, investigator, or

institution

 Incarceration of a subject in a research study not approved to involve

prisoners

 New or increased risk  Change in financial interest disclosure

WIRB Reportable Information

27

Protocol deviation that harmed a subject or placed subject at risk of harm

Protocol deviation made without prior IRB approval to eliminate an immediate hazard to a subject

Breach of confidentiality

Subject complaint that cannot be resolved by the research team

Unanticipated adverse device effect

Adverse event or IND safety report that requires a change to the protocol

  • r consent

Adverse event or IND safety report that does NOT require a change to the protocol or consent

WIRB Reportable Information

28

slide-15
SLIDE 15

5/8/2020 15

The form will guide you information is required based on the event you are reporting

WIRB will review the report and if significant, communicate with appropriate parties

If we find that the event does not constitute an increased risk to subjects and there are no remaining subject safety concerns, we will file it without action.

If the sponsor/CRO requires documentation that the event was reported to WIRB, you can provide them the Connexus acknowledgment of receipt.

If the sponsor/CRO needs documentation that the event was filed, contact WIRB Client Services.

Promptly Reportable Information Form

29

Ensure that you comply with your local CHLA requirements for reportable new information:

After submitting your promptly reportable information form to WIRB, send the report by email to the CHLA HSPP office to irbreliance@chla.usc.edu

The CHLA HSPP office will communicate with the CHLA Investigator and Reviewing IRB to assure resolution of all reportable events

30

Reportable Information

slide-16
SLIDE 16

5/8/2020 16 All sites are required to submit a closure report to WIRB.

 Work with your sponsor to decide when the report should be submitted.  Alert WIRB staff by replying to CRRF emails if you plan to close the study before continuing review.

Closure Reports

31

Upcoming Trainings

32

Date Time Description Tuesday, May 12, 2020 1PM – 2:30PM Submitting studies to WIRB as a CHLA researcher

Initial Review Process, Connexus

Wednesday, May 13, 2020 1PM – 2PM Managing your WIRB approved study

Amendments, Continuing Review, Prompt Reporting

Wednesday, May 20, 2020 11AM – 12:30PM Submitting studies to WIRB as a CHLA researcher

Initial Review Process, Connexus

Wednesday, May 27, 2020 3PM – 4PM Managing your WIRB approved study

Amendments, Continuing Review, Prompt Reporting

slide-17
SLIDE 17

5/8/2020 17

General Questions WIRB Client Services (360) 252-2500 | clientservices@wirb.com Escalated/Urgent Questions Carmen Thompson (360) 252-2447 | cbthompson@wirb.com

We Are Here to Partner With You – Contact Us!

33

Thank You